Journal article
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma
R Coulson, SH Liew, AA Connelly, NS Yee, S Deb, B Kumar, AC Vargas, SA O'Toole, AC Parslow, A Poh, T Putoczki, RJ Morrow, M Alorro, KA Lazarus, EFW Yeap, KL Walton, CA Harrison, NJ Hannan, AJ George, CD Clyne Show all
Oncotarget | IMPACT JOURNALS LLC | Published : 2017
Open access
Abstract
Drugs that target the Renin-Angiotensin System (RAS) have recently come into focus for their potential utility as cancer treatments. The use of Angiotensin Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme (ACE) Inhibitors (ACEIs) to manage hypertension in cancer patients is correlated with improved survival outcomes for renal, prostate, breast and small cell lung cancer. Previous studies demonstrate that the Angiotensin Receptor Type I (AT1R) is linked to breast cancer pathogenesis, with unbiased analysis of gene-expression studies identifying significant up-regulation of AGTR1, the gene encoding AT1R in ER+ve/HER2-ve tumors correlating with poor prognosis. However, there is no evi..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This research was supported by grants from the National Breast Cancer Foundation and the CASS Foundation (ALC). We acknowledge the support of Victorian Government's Operational Infrastructure Support Program and the National Health and Medical Research Council (NHMRC) of Australia Grants. ALC is supported by an NHMRC Career Development Fellowship (ID 1062247). We also acknowledge funding from the Sydney Breast Cancer Foundation (S.A.O'T), the RT Hall Foundation (S.A.O'T), Tag Family Foundation (S.A.O'T), and the O'Sullivan family (S.A.O'T).